BUZZ-Scienture jumps after expanding access to hypertension drug

Reuters02-03 21:17
BUZZ-Scienture jumps after expanding access to hypertension drug

** Shares of  drugmaker Scienture Holdings SCNX.O rise 10.34% to $0.4993 premarket

**  Co says it has expanded access to Arbli, its ready-to-use liquid losartan for high blood pressure

**  Losartan treats hypertension, a condition where consistently high blood pressure increases the risk of stroke and heart disease - SCNX

**  Co says Arbli now available at more than 2,500 healthcare sites, with coverage for 100 million insured Americans

** Expects continued Arbli prescription growth in Q1 and wider insurance and pharmacy coverage

** Says its nasal spray for opioid overdose emergencies, Rezenopy, is set for a U.S. launch in Q2 2026

** Shares fell ~92% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment